FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...
Around the world, thriving economies are powered by dynamic private enterprises acting as engines of growth, collaboration and resilience. In Saudi Arabia, the private sector’s role is even more vital ...
Divest and Spin-Off Top Kontrol Product Line: Streamlining our portfolio by providing loyal shareholders with a special dividend and spinning off Top Kontrol as an independent OTCQB company.